Clovis Oncology's CO-1686 Demonstrates Promising Clinical Activity and Safety in Phase I Study

Loading...
Loading...
Clovis Oncology
CLVS
announced today updated findings from the Phase I portion of its ongoing Phase I/II clinical study of CO-1686, the Company's novel, oral, targeted covalent (irreversible) inhibitor of mutant forms of the epidermal growth factor receptor (EGFR) for the treatment of non-small cell lung cancer (NSCLC) in patients with initial activating EGFR mutations as well as the dominant resistance mutation T790M. Interim results from the Phase I dose-escalation portion of this Phase I/II study are being presented today in an oral presentation by Professor Jean-Charles Soria at the IASLC 15th World Conference on Lung Cancer in Sydney. Six RECIST partial responses have been observed to date in nine evaluable T790M positive patients dosed
See full press release
Posted In: NewsGuidanceContractsFDALegalGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...